CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02116777
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:15.022662+00:00
Published At: 2021-03-26T00:00:00+00:00
Record Updated At: 2021-03-26
Results Posted At: 2021-03-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adult Solid Neoplasm", "Childhood Solid Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Malignant Solid Neoplasm", "Refractory Central Nervous System Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-03-26"
protocolSection.identificationModule.nctId: "NCT02116777"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-03-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.